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Can Cardiac Magnetic Resonance Myocardial Scar
Features Affect Treatment Decisions for Patients With
Coronary Artery Disease and Heart Failure?*
Raymond Y. Kwong, MD, MPH, FACC
Boston, MassachusettsWith the growing prevalence of type 2 diabetes,
obesity, and the increasing average age of the popula-
tion, coronary artery disease (CAD) has become an
escalating health care burden in most western coun-
tries. CAD has been the most common cause of death
in the U.S. for decades, and in recent years, this
pattern has become a worldwide phenomenon (1).
Despite the benefits of effective therapies developed in
the past decades, the age-adjusted decline in CAD
mortality in the U.S. has not been paralleled by a
similar reduction in sudden cardiac death (SCD) (2).
Some estimate that with the growing prevalence of
CAD, the absolute number of SCDs is actually on the
rise in the U.S. Although major multicenter studies
have documented the importance of left ventricular
ejection fraction (LVEF) and New York Heart Asso-
ciation functional class as the strongest predictors
of risk for cardiac mortality in survivors of acute
myocardial infarction (MI) (3), more novel risk-
stratifying schemes are undoubtedly necessary in order
to reduce SCD.
See page 34
In this issue of iJACC, Kwon et al. (4) reported
results of an observational study assessing the im-
plications of quantitative analysis of myocardial scar
burden imaged by contrast-enhanced cardiac mag-
netic resonance (CMR) imaging to patient all-cause
survival or a need for cardiac transplantation. The
authors studied 349 patients with documented isch-
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Cardiovascular Division, Department of Medicine, Brigham
and Women’s Hospital, Boston, Massachusetts.emic cardiomyopathy who were referred for assess-
ment of myocardial viability by CMR. The authors
performed cine steady-state free precession and late
gadolinium enhancement (LGE) CMR imaging
using standard techniques. Post-processing was
carefully performed by semi-quantitative grading of
segmental scar score, transmurality score, average
segmental transmurality, and quantitative measure-
ment of scar extent as a percentage of the total
myocardium (scar percent), blinded to clinical out-
come. After a mean follow-up of 2.6 years, 51
patients died and 5 underwent cardiac transplanta-
tion. Using Cox proportional regression analysis, it
was concluded that quantitative scar percent and
semi-quantitative average transmurality were the
strongest predictors of death or cardiac transplan-
tation. In particular, quantitative scar % was the
strongest predictor of the combined events by
multivariable selection. The strengths of the study
include the relatively large number of patients and
the long clinical follow-up in this high-risk group.
The authors should be commended for their efforts
in using quantitative or semi-quantitative LGE
techniques in studying this group of very sick CAD
patients with moderate to severe left ventricular
dysfunction and a high burden of myocardial scar
(average LVEF was approximately 24%, with scar
involving 31% of the myocardium). This group
represents not only the subset of CAD patients at
the highest risk (15% mortality over mean
follow-up of 2.6 years), but also those who poten-
tially can gain the most from novel or even invasive
therapeutic options. In this clinical scenario, novel
noninvasive risk stratification can therefore be po-
tentially invaluable in making treatment decisions.
In conjunction with other reports, this study
provides adjunctive and growing evidence of patient
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46rognostication using high-resolution myocardial
issue characterization by CMR (5–7). Kwon et al.
4) also provided compelling evidence that in high-
isk CAD patients presenting with moderate to
evere global dysfunction, scar burden provided an
ncremental patient prognosis to LVEF, which can
e affected by the patient’s hemodynamic states and
yocardial loading conditions. Owing to a high
ontrast-to-noise ratio of LGE imaging, quantita-
ive and reproducible analysis can be achieved rap-
dly after imaging, allowing more precise measure-
ent of nonviable myocardial extent than with
onventional nuclear techniques. However, readers
eed to consider several issues before these poten-
ially encouraging results can be applied clinically.
Clinical presentation of infarction and timing from
n index acute MI, among other factors, may modify
he prognostic implication of the results by Kwon et
l. (4). Population-based studies have indicated that
atients found to have clinically silent myocardial
nfarction experienced a 10-year mortality of more
han 45% (8,9). In the current study, details regarding
he proportion of patients with a clinical history of MI
r electrocardiographic evidence of a previous MI
ere not available. Therefore, it is unclear how many
f these patients who were found to have LGE
uffered clinically unrecognized MI. Patients found to
ave clinically unrecognized MI by LGE represent a
articularly high-risk group of CAD patients and are
ikely to follow a survival distribution worse than that
f patients who suffer a clinical MI. In addition,
vailable clinical data suggest that there are bimodal
isk periods after hospital discharge after an acute MI
10). SCD risk seems to be highest in the first several
onths after MI (11) during the unstable myocardial
ealing phase; this is followed by a lower long-term
isk phase of subacute and a chronic phase of adverse
ardiac remodeling. Quantitative assessment of myo-
ardial scar, such as transmurality, scar mass, and
ercent of myocardium, are likely dynamic markers of
ost-MI remodeling that have different prognostic
mplications at different stages after an acute MI. In
he current study, details regarding timing from the
cute MI presentation were not provided. The ideal
rognostic tool will need to incorporate the dynamism
f remodeling risk, assessing these quantifiable
hanges at 2 or more time points after an acute MI.
hese must be addressed in future studies.
Apart from myocardial scar extent and LVEF,
xquisite details of the left ventricular anatomy in 3
imensions can aid treatment decisions. CMR can
ffer accurate assessment of the severity of the left
entricular geometric distortion and mitral regurgi- Mation, which are factors that should be considered
n selecting patients who may benefit from left
entricular or mitral valvular reconstructive surgery.
t our institution, many cardiac surgeons routinely
se CMR to gauge these variables, in addition to
car location and extent, in planning and assessing
esults before and after performing a Dor proce-
ure. Owing to high spatial resolution and tissue
ontrast of LGE imaging by CMR, novel infarct
haracteristics such as microvascular obstruction
12,13), peri-infarct zone (6), and infarct surface
rea (14) by CMR have shown strong promise,
eyond the predictive value of infarct size and
VEF, as novel predictors of patient mortality or
urrogates of adverse cardiac events.
Increasing evidence supports the use of CMR
GE in addressing specific issues in the manage-
ent of ischemic cardiomyopathy. Bleeker et al.
15) reported the use of LGE to identify nonre-
ponders to cardiac resynchronization therapy be-
ond echocardiographic criteria of dysynchrony.
im et al. (16) showed, in a landmark study, how
he transmural extent of infarction accurately pre-
icts segmental recovery of contractile function
iven successful coronary revascularization. Bello et
l. (17) provided evidence of how benefits from
eta-blocker therapy in ischemic heart failure pa-
ients can be predicted from LGE imaging. How-
ver, how we can use this information contributed
y Kwon et al. (4) in guiding treatment decisions in
hese high-risk patients will need studies. Can
uantifiable scar markers guide the implantation of
nternal cardioverter defibrillators to prevent SCD
eyond the predictive value of LVEF? Possibly, but
ithout information regarding the cause of death
cardiac or noncardiac, SCD or not), the relation-
hip between scar extent and any likelihood of a
ife-threatening arrhythmic event will need further
nvestigation. Is it more useful to assess the extent
f viable myocardial segments, rather than the
xtent of myocardial scar, in selecting patients for
igh-risk revascularization surgery? Can the infor-
ation provided by CMR lead to better treatment
lanning and at least improved symptoms or quality
f life? Results using CMR from the anticipated
TICH (Surgical Treatment of Ischemic Heart
ailure) trial and other multicenter efforts may
ddress some of these issues.
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